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1. Background
The South African Lysosomal Storage Disorder (LSD) Medical Advisory 
Board (MAB) is a multidisciplinary/multispecialty team of physicians 
from academic and private healthcare institutions with an interest in 
treating LSDs. The multidisciplinary approach is essential because 
of the multisystem nature of the disorders. The LSD MAB members 
are independent and aim to provide a shared-care model for treating 
physicians and funders regarding various aspects of care for these patients. 
The original UK 2005 National Guidelines for Gaucher Disease1,2 
are based on limited natural history and literature available at 
that time. Since these guidelines were written, three important 
publications have emerged.3-5 They demonstrate a dose response 
to enzyme replacement therapy of up to 60 U/kg every other week 
(EOW) on haematological and visceral parameters, a similar dose 
response on bone mineral density, and a relationship between timing 
of initiation of therapy and reduced risk of avascular necrosis.1-3
The South African guidelines are based primarily on the UK 
guidelines. However, the LSD MAB included evidence from 
subsequent publications to provide an international standard of 
care, but also realistic for South Africa, given the constraints facing 
healthcare workers and patients. These guidelines are intended to 
enable all patients suffering from Gaucher disease to be diagnosed 
and offered the best possible care available.
Since Gaucher disease is rare, it is difficult to obtain large numbers 
of patients for studies. The availability of effective treatment makes 
randomised control studies ethically difficult to design and perform. 
Thus most of the data are derived from case reports and registries. 
2. Disease overview
Gaucher disease is an autosomal recessive lysosomal glycosphingolipid 
storage disorder resulting from a deficiency of the lysosomal enzyme 
acid β-glucosidase (glucocerebrosidase).1 It is the most prevalent 
of the LSDs and is divided into 3 clinical types, of which type 1 is 
by far the most common.1 This partial enzyme deficiency results in 
accumulation of glycosphingolipid-laden macrophages (Gaucher 
cells) throughout the liver, spleen, bone marrow, skeleton and 
occasionally the lung.1 In types 2 and 3 pathology also occurs within 
the brain.1 The onset of clinical features may occur at any age in type 
1 disease, while type 2 presents in infancy and type 3 typically in early 
childhood.1 Early onset in type 1 disease predicts a more aggressive 
course.1 Gaucher disease has been demonstrated to occur in all 
ethnic groups in South Africa. Some population groups such as the 
Ashkenazi Jews have a higher incidence.
3. Diagnosis
The diagnosis of Gaucher disease is based on history, clinical 
evaluation, laboratory investigations and diagnostic imaging.
3.1 Baseline assessments1
History, including family pedigree: medical history of painful hips, 
bone crises, fractures, orthopaedic interventions; surgical history, 
including splenectomy; history of respiratory tract infections or other 
frequent infections; history of eye movement abnormalities, squints; 
history of bleeding, bruising, blood transfusions, nose bleeds, onset of 
menarche and/or heavy menstruation; history of hepatosplenomegaly 
or abdominal distension.
3.2 Clinical assessments1
Height, weight, blood pressure and urine analysis; evidence of 
corneal opacification should be sought; oculomotor gaze palsies and 
pingueculae; presence of jaundice, pallor, ecchymoses, purpura and 
petechiae; spinal deformity, defects of joint movement particularly 
hip assessment; presence of visceromegaly (hepatosplenomegaly) 
and signs of chronic liver disease; neurological evaluation to include 
symptoms of parkinsonism for evaluation of type of Gaucher disease; 
and quality of life questionnaire.
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Objective. These guidelines aim to provide a standard of care 
for patients with Gaucher disease in keeping with international 
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Recommendations. All healthcare professionals involved in the 
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3.3 Laboratory evaluations1
•	 Baseline enzyme activity of glucocerebrosidase in leukocytes
•	 DNA mutational analysis (at baseline only)
•	 Bone marrow aspiration is not required for diagnosis.
Recommended:1 
•	 Chitotriosidase activity is elevated in Gaucher disease (except 
in a small proportion of patients where it is absent due to a 
mutation that can be identified by DNA mutation analysis), and 
can be assessed at baseline and as required to monitor disease 
activity. Other biomarkers which decrease with effective enzyme 
replacement include serum angiotensin-converting enzyme (ACE) 
and tartrate-resistant acid phosphatase (TRAP).
•	 Full blood count (FBC) with peripheral smear, vitamin B12, folate, 
iron and ferritin.
•	 Endocrine profile: parathyroid hormone (PTH) & 25-OH vitamin 
D & thyroid-stimulating hormone (TSH) (free thyroxine (T4) & 
free triiodothyronine (T3) when indicated).
•	 Biochemistry profile: renal, liver and lipid profiles, C-reactive 
protein (CRP), immunoglobulins, serum protein electrophoresis.
•	 Clotting screen: international normalised ratio (INR), prothrombin 
time (PT), partial thromboplastin time (PTT) (factor XI levels and 
fibrinogen when necessary, particularly in pregnancy).
•	 Serum storage for antibody screening (store for baseline) with 
protocol and informed consent.
•	 HIV screening with informed consent; and hepatitis screen.
For timing of tests refer to section 7 (some blood tests are not 
available in South Africa and can be done in a European laboratory or 
specimens collected and frozen for later analysis as required).
3.4 Diagnostic and follow-up imaging1
3.4.1 Magnetic resonance imaging (MRI): abdomen and high-risk 
bones (femur, humerus, lumbar vertebrae, hip joints) at baseline, 
when clinically indicated and at dose adjustments: (i) initial 
assessment, staging and calculation of organ volumes; (ii) visceral 
infarction – only if necessary for clinical evaluation; (iii) new 
symptoms suggestive of bone or joint disease (bone marrow burden 
score6 is optional). MRI is valuable for assessment of structural bone 
abnormalities. 
3.4.2 Dual energy X-ray absorptiometry (DEXA): at baseline and 
as needed. Identification of patients at risk of fractures, and prior to 
and at follow-up of patients requiring antiresorptive or anabolic bone 
therapy. For paediatric patients, DEXA scan must be performed at 
a centre that uses paediatric reference values. DEXA measurements 
should be done at bone sites that are free of osteonecrosis. DEXA is 
the method of choice for evaluating osteopenia/osteoporosis.
3.4.3 Plain radiology: skeletal survey when clinically indicated for 
acute bone crisis or diagnosis of fracture; chest X-ray (CXR) for 
suspected pulmonary involvement. 
3.4.4 Ultrasound: organ measurement (liver and spleen size when 
volumetric MRI not available), gall stones, portal hypertension or chronic 
liver disease, renal involvement. Heel ultrasound if indicated to assess 
bone involvement if evaluation at other sites not possible by DEXA. 
3.5 Cardiopulmonary evaluation1
CXR, pulmonary function tests and electrocardiogram (ECG) at baseline 
and as indicated. Echocardiography in selected patients to confirm or 
refute the suspicion of pulmonary hypertension or cardiomyopathy.
4. Treatment
4.1 Criteria for treatment1
In general, presentation with clinical features of Gaucher disease;7 
one aim of intervention in such patients is primary prevention of 
irreversible organ damage, including bone, spleen or liver damage,8 
pulmonary9 and neurological complications.1
4.2 When to start – indications for specific treatment1,9
Immediate initiation of treatment: 
•	 Clinically significant thrombocytopenia or anaemia
•	 History of progressive organomegaly (hepatosplenomegaly)
•	 Bone involvement
•	 Growth failure/retardation
•	 Delayed puberty
•	 Pulmonary involvement
•	 History of splenectomy
•	 Impairment of function (physical and quality of life)
•	 Any child with disease manifestations should be treated.
4.3 Treatment options
4.3.1 Enzyme replacement therapy (ERT):1 imiglucerase, an 
analogue of human intracellular glucocerebrosidase, is the treatment 
of choice for types 1 and 3 Gaucher disease. 
4.3.2 Supportive therapy:1 indicated for those patients who decline 
the above option (usually elderly patients) and require symptomatic 
supportive intervention with blood products, bisphosphonate 
therapy, and/or analgesia. 
4.3.3 Mobility aids:1 e.g. crutches and wheelchairs to aid mobility for 
everyday living. 
4.3.4 Experimental therapies:1 might become available and will need 
further evaluation at such time.
4.3.5 Monitoring:1 patients identified with Gaucher disease 
mutations, who may be asymptomatic, do not require treatment at 
present, but must be monitored regularly (6-monthly) for disease 
progression according to the goals of treatment (section 5) and 
indications to start therapy as above. Treatment options for all 
patients must be reviewed according to clinical and laboratory data.
4.3.6 Bone marrow transplantation:1 no longer advocated for type 1 
patients now that effective ERT is available; may still be considered 
under certain circumstances for type 3 patients when a matched, 
unaffected sibling donor has been identified.
4.3.7 Other therapies: substrate reduction therapy is currently 
utilised in some patients with mild disease. It is currently not 
available in South Africa.
4.3.8 Genetic counselling:1 this is an important component of supportive 
care for any family and best provided by a healthcare professional 
well versed in these aspects of care. Parents of affected individuals, 
individuals themselves when they reach an age of understanding, siblings 
of carriers or affected individuals, and spouses/potential spouses should 
be included. Genetic counselling aims to enable the patients and their 
families to understand the medical facts, role of inheritance, strategies 
to prevent recurrence and to make the best possible adaptation to the 
disorder. Autosomal recessive inheritance implies that both parents of 
an affected person are carriers of a mutated acid β-glucosidase gene. 
The affected child has inherited a mutated copy from each parent. The 
parents have a 25% chance for another affected child in subsequent 
pregnancies. The affected person must also understand the risk of 
transmission of a mutated gene to their offspring. 
Carrier testing is therefore important for these families. Whereas 
enzyme activity is a reliable method for the diagnosis of Gaucher 
disease, its use for identifying carriers is limited. The best method for 
carrier testing and prenatal diagnosis is mutation analysis. 
4.4 Imiglucerase treatment – dosing regimen10
The only product currently registered for Gaucher disease in South 
Africa is imiglucerase that is administered by intravenous infusion 
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over 1 - 2 hours. Dosage should be individualised to each patient 
and dosage adjustments made on an individual basis. This may 
increase or decrease, based on achievement of therapeutic goals 
as assessed by routine comprehensive evaluations of the patient’s 
clinical manifestations. Dose is also partly determined by the 
requirement to use whole vials of imiglucerase, which is available 
in 400 U vials. Therapy may be continued throughout pregnancy at 
the discretion of the treating physician.11 
4.4.1 Dose selection based on severity: demonstration of a dose response 
to imiglucerase for haematological and visceral parameters3 and bone 
mineral density1 implies a need and provides a rationale for initial 
dose selection based on clinical severity, followed by dose titration (up 
or down) according to achievement of therapeutic goals, and specific 
symptoms that are considered severe or higher risk. In specific cases, dose 
adjustments might be required according to clinical need.
Patients fulfilling one of the severe or high-risk criteria should start 
imiglucerase at a recommended dose of 30 - 60 U/kg every other week 
(EOW). All other patients, not fulfilling high-risk criteria, but fulfilling 
the ‘indications for specific treatment’, should commence imiglucerase 
at a recommended dose of 10 - 30 U/kg EOW (see 4.4.2).
4.4.2 Severe or high-risk disease (30 - 60 U/kg EOW): one of the 
following criteria:
•	 Symptomatic paediatric patients identified with severe genotypes 
known to be associated with rapid disease progression
•	 Paediatric patients prior to epiphyseal closure with evidence of 
growth failure and/or delayed puberty
•	 The presence of bone disease comprising bone crises, bone pain, 
pathological fracture, radiological evidence of osteonecrosis, 
infarction or generalised osteopenia (previous joint replacement 
will be considered an indication of severe bone disease)
•	 Splenectomy
•	 Significant splenomegaly as indicated by: spleen volume at least 6 
times normal OR at risk of splenic rupture OR severe symptoms 
of abdominal distension or pain OR hypersplenism OR episodes 
of splenic infarction
•	 Evidence of hepatic infarction or cirrhosis or complications
•	 Transfusion dependency OR coagulopathy OR platelets under 
20 000/µl (20×109/l)
•	 Pulmonary involvement
•	 Type 3 Gaucher disease.
There are no known drug interactions with imiglucerase.10 
Co-morbidities are not an indication to withhold therapy.10 Refer 
to the South African prescribing information for imiglucerase.
5. Goals of treatment 
5.1 Treatment goals for anaemia1,9 (Table 1)
Achieve acceptable levels of haemoglobin (Hb); eliminate blood 
transfusion dependency; reduce fatigue, dyspnoea, angina; maintain 
improved Hb values achieved after the first 12 - 24 months of 
therapy.
Treatment response may vary. Mild anaemia may persist especially 
in patients with severe splenic enlargement.8
5.2 Treatment goals for thrombocytopenia1,9 (Table 2)
All patients: increase platelet counts during the first year of 
treatment sufficiently to prevent surgical, obstetric and spontaneous 
bleeding.
Splenectomised patients: normalisation of platelet count by 1 year 
of treatment.
Patients with intact spleen: 
•	 Moderate baseline thrombocytopenia (60  000 - 120 000/µl): 
the platelet count should increase by 1.5 to 2-fold by year 1 and 
approach low-normal levels by year 2
•	 Severe baseline thrombocytopenia (<60 000/µl): the platelet count 
should increase by 1.5-fold by year 1 and continue to increase 
slightly during years 2 - 5 (doubling by year 2), but normalisation 
is not expected 
•	 Avoid splenectomy (may be necessary for life-threatening 
haemorrhagic events) 
•	 Maintain stable platelet counts to eliminate risk of bleeding after a 
maximal response has been achieved. 
Treatment response may vary.9
5.3 Treatment goals for splenomegaly1,9 (Fig. 1)
Reduce and maintain spleen volume to ≤2 - 8 times normal; reduce 
the spleen volume by 30 - 50% within year 1 and by 50 - 60% by years 
2 - 5; alleviate symptoms due to splenomegaly: abdominal distension, 
early satiety and new splenic infarction; eliminate hypersplenism; 
avoid splenectomy. 
Treatment response may vary. Patients with severe splenic 
enlargement may not experience decrease to normal size.8
5.4 Treatment goals for hepatomegaly1,9 (Fig. 2)
Reduce and maintain the liver volume to/at 1.0 - 1.5 times normal 
(according to body weight); reduce the liver volume by 20 - 30% 
within years 1 - 2 and by 30 - 40% by years 3 - 5.
Table 1. Anaemia treatment goals1,9
Patients Goal Time 
frame
Adult females and 
children
Haemoglobin ≥10.0 g/dl Years 1 - 2
Male patients >12 years Haemoglobin ≥12.0 g/dl Years 1 - 2
All patients Eliminate blood 
transfusion dependency
Reduce fatigue
Maintain improved 
haemoglobin levels
Table 2. Thrombocytopenia treatment goals1,9
Patients Goal Time frame
All patients Sufficient platelets to reduce bleeding Year 1
Patients without spleen Normalisation of platelet counts Year 1
Patients with spleen
Moderate thrombocytopenia (>60 000/µl - <120 000/µl)
Low-normal platelet counts
(1.5 to 2-fold increase within first year) Year 2
Severe thrombocytopenia
(<60 000/µl)
Continued increases but no normalisation (1.5-fold 
increase within first year) Year 2
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Treatment response may vary. Patients with severe hepatic 
enlargement may not experience decrease to normal size.9
5.5 Treatment goals for skeletal pathology (Table 3)1,9 
Lessen or eliminate bone pain within 1 - 2 years; prevent bone crises; 
prevent osteonecrosis and subchondral joint collapse; improve bone 
mineral density (BMD) – adult patients: increase BMD within 3 - 5 
years.
Improve Bone Marrow Burden Score by 50% within 2 - 3 years 
(measured by MRI).6
5.6 Treatment goals for pulmonary involvement1,9 
Reverse hepatopulmonary syndrome and dependency on oxygen; 
ameliorate pulmonary hypertension (ERT plus adjuvant therapies); 
improve functional status and quality of life; prevent rapid deterioration 
of pulmonary disease and sudden death; prevent pulmonary disease by 
timely initiation of ERT and avoidance of splenectomy. 
5.7 Treatment goals for functional health and well-
being1,9
•	 Improve or restore physical function for carrying out normal daily 
activities and fulfilling functional roles
•	 Improve scores from baseline of a validated quality of life 
instrument within 2 - 3 years or less depending on disease burden.
5.8 Treatment goals for other parameters9
Physical examination results should improve; stabilise or decrease 
serial measurements of the biomarkers such as chitotriosidase, TRAP, 
or ACE.
6. Safety information
6.1 Adverse effects of imiglucerase10 
Approximately 15% of patients treated and tested have developed 
IgG antibodies to imiglucerase during the first year of therapy. 
Patients who developed IgG antibodies usually did so within 6 
months of treatment and rarely developed antibodies to imiglucerase 
after 12 months of therapy. Approximately 46% of patients with 
detectable IgG antibodies experienced symptoms of hypersensitivity. 
Patients with antibodies to imiglucerase have a higher risk of 
hypersensitivity reaction. Conversely, not all patients with symptoms 
of hypersensitivity have detectable IgG antibody. It is suggested 
that patients be monitored periodically for IgG antibody formation 
during the first year of treatment. 
Treatment with imiglucerase should be approached with caution 
in patients who have exhibited symptoms of hypersensitivity to the 
product. Anaphylactoid reactions have been reported in less than 
1% of the patient population. Further treatment with imiglucerase 
should be conducted with caution in these patients. Most patients 
have successfully continued therapy after a reduction in the infusion 
rate and pretreatment with antihistamines and/or corticosteroids.
Adverse event forms should be submitted to the Medicines Control 
Council and/or the relevant pharmaceutical company. 
7. Follow-up assessment (also refer to 
Section 3.3)
7.1 Timing1
•	 Every 3 months until stable, then 6-monthly:
•	 Clinical evaluation of haematological, visceral, skeletal and, 
where appropriate, neurological disease and application 
of a validated health-related quality of life instrument are 
recommended
•	 Biomarkers including chitotriosidase, ACE and/or TRAP
•	 Blood tests including FBC, liver enzymes and immunoglobulins, 
as well as other specific investigations depending on baseline 
results and ongoing co-morbidities.
•	 IgG drug-specific antibody assessment as clinically indicated. 
•	 MRI volumetric evaluation of liver and spleen; 2-yearly for stable 
patients, sooner if indicated.
•	 Imaging of bones as clinically indicated. 
7.2 Asplenic patients 
Asplenic Gaucher disease patients are at increased risk of 
osteonecrosis,12,13 pulmonary hypertension,14 cholelithiasis,15 and liver 
Fig. 1. Splenomegaly treatment goals (adapted from Pastores et al.9).
Fig. 2. Hepatomegaly treatment goals (adapted from Pastores et al.9)
Table 3. Bone disease treatment goals1,9
Patients Goals Time frame
All patients Lessen or eliminate bone pain
Prevent bone crises
Prevent osteonecrosis and subchondral joint collapse
1 - 2 years
Paediatric patients Attain normal or ideal peak skeletal mass
Increase cortical and trabecular bone mineral density (z-score not t-score)
Year 2
Adults Increase cortical and trabecular bone mineral density 3 - 5 years
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cirrhosis.16 Monitoring therapy by serial measurement of haemoglobin 
and platelet counts is usually unhelpful. Spleen size clearly cannot be 
used to monitor response to treatment, therefore particular attention 
should be paid to systemic and bony symptoms and to biomarkers of 
disease in order to prevent episodes of bone infarction.
Asplenic patients (especially females) are at increased risk of 
pulmonary hypertension. Clinicians should maintain a high index of 
suspicion for this complication. ECG, echocardiogram and Doppler 
studies should be performed yearly.
Overwhelming sepsis is a principal complication of the asplenic 
state, mainly as a result of infection with Gram-positive encapsulated 
organisms (i.e. Streptococcus pneumoniae).17 
7.3 Management of asplenic patients1 
Ensure that patients who have undergone splenectomy have received 
the following immunisations: 
•	 Haemophilus influenzae type b (Hib)
•	 Pneumococcal polyvalent vaccine repeated every 5 years (for 
children under 10 years give two doses of pneumococcal conjugate 
vaccine 2 months apart followed by a dose of polyvalent vaccine 2 
months later)
•	 Influenza annually.
Long-term regular antibiotic prophylaxis with penicillin V 250 mg 
bd or erythromycin 250 mg bd, if allergic to penicillin, is mandatory.
If possible, patients should carry a standard medical information 
card stating: ‘I have no functioning spleen.’ Patients should be warned 
that they are at increased risk of sepsis. 
8. Adjuvant therapy1
Adult patients may benefit from bisphosphonate therapy either 
orally (which can be prescribed by their general practitioner) 
or intravenously. Little evidence as to the efficacy of this 
treatment in Gaucher disease is available. Guidelines for the use 
of bisphosphonates should be similar to those of other causes of 
osteopenia/osteoporosis.
8.1 Other treatment considerations 
Vitamin D, calcium may be considered; specific pain medication;1 
seizure/neurological management; pulmonary hypertension 
management.1 There are no known drug interactions with 
imiglucerase; therefore co-morbidities are not an indication to 
withhold therapy.10
9. Surgical management1
Orthopaedic surgical intervention is commonly required to restore 
function and correct deformity. Subchondral bone collapse as a 
result of avascular necrosis leads to pain and loss of function and 
may require joint replacement, most commonly of the hip joint, but 
also of the knee and shoulder.18 Given that joint replacement is often 
carried out at a young age, there is frequent requirement for complex 
revision surgery. 
Gallstone disease is also more prevalent in Gaucher disease.13 
Peri-operative medical management of Gaucher disease patients 
must take account of: (i) the risk of infection in the asplenic patient; 
and (ii) the risk of bleeding associated with thrombocytopenia, platelet 
function defects and coagulopathies associated with the condition. 
10. Indications for cessation of 
treatment1
Specific treatment may be withdrawn, following careful discussion 
with the patient and the multidisciplinary team, under the following 
circumstances: 
•	 Intolerable and unavoidable adverse effects; intercurrent illness.
•	 Where long-term quality of life or expected survival is such that 
the patient will gain no significant benefit from specific treatment 
for Gaucher disease.
•	 Lack of responsiveness to treatment, having made all appropriate 
dose adjustments and measures to improve effectiveness of 
treatment. This applies in the unlikely event of complete resistance 
to treatment and to irreversible progression of individual aspects 
of Gaucher disease (most likely neurological) whereby the patient’s 
quality of life is very poor and where there is little or no prospect 
of response to treatment.
•	 At the request of the patient, or properly allocated guardian acting 
in the patient’s best interests, if the patient is properly deemed not 
competent.
•	 If the circumstances of the patient’s lifestyle are such that sufficient 
compliance with treatment is not possible. Such cases might 
include intravenous drug abuse associated with a peripatetic 
lifestyle.
•	 If the health and well-being of medical and/or nursing staff are 
placed under significant threat as a result of the actions or lifestyle 
of the patient.
11. Role of the Lysosomal Storage 
Disorder Medical Advisory Board 
11.1 Interaction between treating physicians and the 
LSD MAB 
The MAB will act as consultants to assist treating physicians in the 
management of their patients.
11.2 Interaction between medical aid organisations and 
the LSD MAB 
Medical aids/funders may consult the MAB regarding patients new to 
treatment or when dosage adjustments are requested.
Disclaimer. These guidelines were prepared for physicians and other 
healthcare professionals on behalf of the LSD MAB and reflect the best 
data available at the time. Caution should be exercised in interpreting 
the data; future studies may require alteration of the conclusions or 
recommendations in this report. It may be necessary or even desirable 
to depart from the guidelines in the interests of specific patients and 
special circumstances. These guidelines do not represent all the possible 
methods of management applicable to all patients, do not exclude any 
other reasonable methods, and will not ensure successful treatment 
in every situation. The unique circumstances of each patient must be 
taken into account by the responsible physician making decisions on any 
specific therapy. Just as adherence to these guidelines may not constitute 
defence against a claim of negligence, so deviation from them should not 
necessarily be deemed negligent.
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Appendix 1. Laboratory investigations 
Test Laboratory 
Enzyme activity of glucocerebrosidase in leukocytes (baseline only) NHLS: 1 - 2 ACD tubes to be kept cool but not frozen – must reach 
Johannesburg within 24 hours (011-489-9220)
Chitotriosidase activity NHLS: 1 serum tube (yellow) to be handled as above (011-489-9220)
DNA mutational analysis (in patients with low chitotriosidase activity) NHLS: 2 EDTA tubes to be handled as above (011-489-9226)
Full blood count and peripheral smear Routine haematology laboratories 
Vitamin B12, folate, ferritin, (urinary and serum lysosome are optional) Routine clinical chemistry laboratories 
Endocrine profile to include parathyroid hormone (PTH), 25-OH 
vitamin D and thyroid-stimulating hormone (TSH)
Routine clinical chemistry laboratories 
Biochemistry profile including renal, liver and lipid profiles, serum 
angiotensin-converting enzyme (ACE), C-reactive protein (CRP), 
tartrate resistant acid phosphatase (TRAP), immunoglobulins, serum 
protein electrophoresis (lipoprotein-a, homocystine and lactate 
dehydrogenase are optional) 
Routine clinical chemistry laboratories 
Clotting screen to include factor XI levels and fibrinogen Haemostasis laboratory (must be delivered fresh to the laboratory for 
analysis)
Serum storage for antibody screening Provision of long-term storage facilities warranted
Appendix 2. Diagnostic imaging 
Modality  Frequency  Rationale 
MRI abdomen, MRI bone At baseline and 12 - 
18-monthly follow-up or 
when clinically indicated 
Initial assessment, staging and calculation of organ volumes. Visceral 
infarction 
New symptoms suggestive of bone or joint disease. Bone marrow fat 
fraction (preferable, if available) 
DEXA Every 2 years (recommended) Selection of patients at risk for fractures. Prior to and at follow-up in 
patients requiring antiresorptive or anabolic bone therapy 
Plain radiology skeletal survey At baseline, every 5 years Acute bone crisis, diagnosis of fracture. Pulmonary involvement 
Ultrasound abdomen 
Heel bone ultrasound 
Only if indicated Organ measurement. Gallstones, portal hypertension or chronic liver 
disease. Renal involvement 
If other sites not accessible to DEXA 
Echocardiography In selected patients To confirm or refute the suspicion of pulmonary hypertension or 
cardiomyopathy 
MRI = magnetic resonance imaging; DEXA = dual energy X-ray absorptiometry.
